Nxera Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Nxera Pharma has a total shareholder equity of ¥67.8B and total debt of ¥64.9B, which brings its debt-to-equity ratio to 95.8%. Its total assets and total liabilities are ¥152.3B and ¥84.6B respectively.
Key information
95.8%
Debt to equity ratio
JP¥64.90b
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥48.87b |
| Equity | JP¥67.76b |
| Total liabilities | JP¥84.58b |
| Total assets | JP¥152.34b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: JSS's short term assets (¥59.9B) exceed its short term liabilities (¥14.9B).
Long Term Liabilities: JSS's short term assets (¥59.9B) do not cover its long term liabilities (¥69.6B).
Debt to Equity History and Analysis
Debt Level: JSS's net debt to equity ratio (23.7%) is considered satisfactory.
Reducing Debt: JSS's debt to equity ratio has increased from 4% to 95.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable JSS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: JSS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 12.7% per year.